Stocks & Investing
Stocks and Investing
Stocks and Investing
Mon, February 7, 2022
[ Mon, Feb 07th 2022
] - WOPRAI
[ Mon, Feb 07th 2022
] - WOPRAI
[ Mon, Feb 07th 2022
] - WOPRAI
[ Mon, Feb 07th 2022
] - WOPRAI
[ Mon, Feb 07th 2022
] - WOPRAI
[ Mon, Feb 07th 2022
] - WOPRAI
[ Mon, Feb 07th 2022
] - WOPRAI
[ Mon, Feb 07th 2022
] - WOPRAI
[ Mon, Feb 07th 2022
] - WOPRAI
[ Mon, Feb 07th 2022
] - WOPRAI
[ Mon, Feb 07th 2022
] - WOPRAI
[ Mon, Feb 07th 2022
] - WOPRAI
[ Mon, Feb 07th 2022
] - WOPRAI
[ Mon, Feb 07th 2022
] - WOPRAI
[ Mon, Feb 07th 2022
] - WOPRAI
[ Mon, Feb 07th 2022
] - WOPRAI
[ Mon, Feb 07th 2022
] - WOPRAI
[ Mon, Feb 07th 2022
] - WOPRAI
[ Mon, Feb 07th 2022
] - WOPRAI
[ Mon, Feb 07th 2022
] - WOPRAI
[ Mon, Feb 07th 2022
] - WOPRAI
[ Mon, Feb 07th 2022
] - WOPRAI
[ Mon, Feb 07th 2022
] - WOPRAI
[ Mon, Feb 07th 2022
] - WOPRAI
[ Mon, Feb 07th 2022
] - WOPRAI
[ Mon, Feb 07th 2022
] - WOPRAI
[ Mon, Feb 07th 2022
] - WOPRAI
Fri, February 4, 2022
[ Fri, Feb 04th 2022
] - WOPRAI
[ Fri, Feb 04th 2022
] - WOPRAI
[ Fri, Feb 04th 2022
] - WOPRAI
Evan Seigerman Downgraded (BIIB) to Hold and Decreased Target to $238 on, Feb 4th, 2022
Evan Seigerman of BMO Capital, Downgraded "Biogen Inc." (BIIB) to Hold and Decreased Target from $260 to $238 on, Feb 4th, 2022.
Evan has made no other calls on BIIB in the last 4 months.
There are 17 other peers that have a rating on BIIB. Out of the 17 peers that are also analyzing BIIB, 11 agree with Evan's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Carter Gould of "Barclays" Maintained at Hold with Decreased Target to $244 on, Thursday, January 20th, 2022
- Yatin Suneja of "Guggenheim" Downgraded from Strong Buy to Hold and Decreased Target to $202 on, Thursday, January 13th, 2022
- Salim Syed of "Mizuho" Maintained at Hold with Decreased Target to $207 on, Wednesday, January 12th, 2022
- Laura Chico of "Wedbush" Maintained at Hold with Decreased Target to $195 on, Wednesday, January 12th, 2022
- Christopher Raymond of "Piper Sandler" Downgraded from Buy to Hold and Decreased Target to $216 on, Wednesday, January 12th, 2022
- Geoff Meacham of "B of A Securities" Maintained at Hold with Decreased Target to $275 on, Thursday, December 23rd, 2021
- Cory Kasimov of "JP Morgan" Maintained at Hold with Decreased Target to $276 on, Tuesday, December 21st, 2021
- Brian Skorney of "Baird" Maintained at Hold with Decreased Target to $258 on, Tuesday, December 21st, 2021
- Salveen Richter of "Goldman Sachs" Initiated at Hold and Held Target at $271 on, Monday, December 6th, 2021
- Brian Abrahams of "RBC Capital" Maintained at Hold with Decreased Target to $277 on, Friday, November 19th, 2021
- Alethia Young of "Cantor Fitzgerald" Maintained at Hold with Decreased Target to $327 on, Friday, October 15th, 2021
These are the ratings of the 6 analyists that currently disagree with Evan
- Marc Goodman of "SVB Leerink" Maintained at Buy with Decreased Target to $300 on, Monday, January 24th, 2022
- Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $270 on, Tuesday, January 18th, 2022
- Jay Olson of "Oppenheimer" Maintained at Buy with Decreased Target to $350 on, Wednesday, December 22nd, 2021
- Phil Nadeau of "Cowen & Co." Maintained at Buy with Decreased Target to $375 on, Thursday, October 21st, 2021
- Paul Matteis of "Stifel" Maintained at Strong Buy with Decreased Target to $344 on, Friday, October 15th, 2021
- Michael Yee of "Jefferies" Maintained at Strong Buy with Decreased Target to $400 on, Friday, October 8th, 2021
